Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.
Ontology highlight
ABSTRACT: Despite advances in biomedicine, the incidence and the mortality of hepatocellular carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages leading to the less than optimal outcome of the treatments. Molecular targeted therapy with sorafenib, a dual-target inhibitor targeting the serine-threonine kinase Raf and the tyrosine kinases VEGFR/PDGFR, is at present the main treatment for advanced-stage HCC, either in a single or combinatory regimen. However, it was observed in a large number of patients that its effectiveness is hampered by drug resistance. HCC is highly heterogeneous, within the tumor and among individuals, and this influences disease progression, classification, prognosis, and naturally cellular susceptibility to drug resistance. This review aims to
SUBMITTER: Cabral LKD
PROVIDER: S-EPMC7352671 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA